A new surgical technique utilizing per-operative fluorescence imaging is offering hope for improved outcomes in women diagnosed wiht endometrial cancer. The Cornouaille Hospital Center in Quimper, France, began employing the technology in December 2025, representing a key advancement in localized cancer treatment at the facility, which sees approximately 40 endometrial cancer cases annually. This procedure, utilizing the dye indocyanine green, promises more precise surgical interventions adn reduced patient recovery times, building on existing robotic surgery capabilities.
A new technology is offering more precise surgical options for women battling endometrial cancer. The Cornouaille Hospital Center in Finistère, France, treats approximately 40 women with endometrial cancer each year – a disease that represents the fifth most common cancer diagnosed in women, with 8,432 new cases reported in France in 2023.
Since December 2025, patients at the Quimper hospital have been benefiting from per-operative fluorescence imaging, a technique that enhances visualization during surgery. The procedure involves injecting indocyanine green, a dye that allows surgeons to better observe organ blood supply and lymphatic drainage.
This improved visualization is particularly helpful in identifying sentinel lymph nodes, which are then removed for analysis. “This will allow us to determine if there are or are not cancer cells present, which will then guide treatment decisions,” explains Aurore Foret, head of the gynecological surgery department. “This new technique allows for more precise surgery and reduces morbidity and complications for patients.”
The advancement represents a significant improvement over previous methods like lymphoscintigraphy or the use of patent blue dye, which carried a risk of allergic reactions and took longer to complete, according to Foret. Early and accurate cancer detection is crucial for improving patient outcomes and quality of life.
Expanding Applications
The new equipment cost the Quimper hospital more than 80,000 euros and complements its existing Da Vinci surgical robot, which is also equipped with fluorescence imaging capabilities. Currently, the technology is being used for endometrial and cervical cancers. “With additional equipment, we will be able to use it for breast cancer as well,” Foret anticipates. Further applications are also being explored in urology.
Personalize your news by adding your cities and media to your favorites with Mon Actu.
